CN102416018A - Method for treating cervical erosion by using preparation containing triamcinolone acetonide - Google Patents
Method for treating cervical erosion by using preparation containing triamcinolone acetonide Download PDFInfo
- Publication number
- CN102416018A CN102416018A CN2011103187957A CN201110318795A CN102416018A CN 102416018 A CN102416018 A CN 102416018A CN 2011103187957 A CN2011103187957 A CN 2011103187957A CN 201110318795 A CN201110318795 A CN 201110318795A CN 102416018 A CN102416018 A CN 102416018A
- Authority
- CN
- China
- Prior art keywords
- cervical erosion
- preparation
- triamcinolone acetonide
- usefulness
- percentage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003628 erosive effect Effects 0.000 title claims abstract description 51
- 229960002117 triamcinolone acetonide Drugs 0.000 title claims abstract description 45
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 238000000034 method Methods 0.000 title claims abstract description 30
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 17
- 239000007938 effervescent tablet Substances 0.000 claims abstract description 11
- 239000002674 ointment Substances 0.000 claims abstract description 11
- 230000000699 topical effect Effects 0.000 claims abstract description 4
- 239000000522 vaginal cream Substances 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- 239000000758 substrate Substances 0.000 claims description 19
- -1 cetyl cetylate Chemical compound 0.000 claims description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- 239000002202 Polyethylene glycol Substances 0.000 claims description 13
- 229920001223 polyethylene glycol Polymers 0.000 claims description 13
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 12
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 11
- 210000001215 vagina Anatomy 0.000 claims description 11
- 229920001661 Chitosan Polymers 0.000 claims description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- 108010010803 Gelatin Proteins 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 239000008273 gelatin Substances 0.000 claims description 9
- 229920000159 gelatin Polymers 0.000 claims description 9
- 235000019322 gelatine Nutrition 0.000 claims description 9
- 235000011852 gelatine desserts Nutrition 0.000 claims description 9
- 239000001814 pectin Substances 0.000 claims description 9
- 229920001277 pectin Polymers 0.000 claims description 9
- 235000010987 pectin Nutrition 0.000 claims description 9
- 239000004698 Polyethylene Substances 0.000 claims description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 7
- 229920000573 polyethylene Polymers 0.000 claims description 7
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 7
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 6
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 6
- 229940113124 polysorbate 60 Drugs 0.000 claims description 6
- 239000000853 adhesive Substances 0.000 claims description 5
- 239000006184 cosolvent Substances 0.000 claims description 5
- 239000003974 emollient agent Substances 0.000 claims description 5
- 239000003995 emulsifying agent Substances 0.000 claims description 5
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 5
- 229920000609 methyl cellulose Polymers 0.000 claims description 5
- 239000001923 methylcellulose Substances 0.000 claims description 5
- 235000010981 methylcellulose Nutrition 0.000 claims description 5
- 239000002480 mineral oil Substances 0.000 claims description 5
- 235000010446 mineral oil Nutrition 0.000 claims description 5
- 210000004877 mucosa Anatomy 0.000 claims description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical group [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 229960000282 metronidazole Drugs 0.000 claims description 4
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 4
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 4
- IIGMITQLXAGZTL-UHFFFAOYSA-N octyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCC IIGMITQLXAGZTL-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 229940044977 vaginal tablet Drugs 0.000 claims description 4
- 239000000003 vaginal tablet Substances 0.000 claims description 4
- 239000000230 xanthan gum Substances 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- 235000010493 xanthan gum Nutrition 0.000 claims description 4
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 3
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 3
- 229940042585 tocopherol acetate Drugs 0.000 claims description 3
- 229940044959 vaginal cream Drugs 0.000 claims description 3
- 229940120293 vaginal suppository Drugs 0.000 claims description 3
- 239000006216 vaginal suppository Substances 0.000 claims description 3
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims description 2
- SIIKJNVURODAEF-KVVVOXFISA-N C(CCCCCCCCC)O.C(CCCCCCC\C=C/CCCCCCCC)(=O)O Chemical compound C(CCCCCCCCC)O.C(CCCCCCC\C=C/CCCCCCCC)(=O)O SIIKJNVURODAEF-KVVVOXFISA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 241001597008 Nomeidae Species 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 244000299461 Theobroma cacao Species 0.000 claims description 2
- 235000009470 Theobroma cacao Nutrition 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 229960002227 clindamycin Drugs 0.000 claims description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 2
- 229940110456 cocoa butter Drugs 0.000 claims description 2
- 235000019868 cocoa butter Nutrition 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 2
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000003232 water-soluble binding agent Substances 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims 3
- IPWKIXLWTCNBKN-UHFFFAOYSA-N Madelen Chemical compound CC1=NC=C([N+]([O-])=O)N1CC(O)CCl IPWKIXLWTCNBKN-UHFFFAOYSA-N 0.000 claims 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 claims 1
- 229960004099 azithromycin Drugs 0.000 claims 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 1
- 229960005074 butoconazole Drugs 0.000 claims 1
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 claims 1
- 229960004022 clotrimazole Drugs 0.000 claims 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims 1
- 229960002509 miconazole Drugs 0.000 claims 1
- 229910017604 nitric acid Inorganic materials 0.000 claims 1
- 229960002313 ornidazole Drugs 0.000 claims 1
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims 1
- 229960005053 tinidazole Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 206010047139 Vasoconstriction Diseases 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 3
- 230000025033 vasoconstriction Effects 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000012049 topical pharmaceutical composition Substances 0.000 abstract 1
- 239000000029 vaginal gel Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 13
- 210000003679 cervix uteri Anatomy 0.000 description 11
- 240000008042 Zea mays Species 0.000 description 9
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 9
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 9
- 235000005822 corn Nutrition 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000002156 mixing Methods 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010065019 Coital bleeding Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010053636 Obstetric infection Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a method for treating or preventing cervical erosion by applying a topical preparation containing triamcinolone acetonide. Such formulations may be triamcinolone acetonide and other excipients, or a combination of triamcinolone acetonide and one or more antibiotics. The treatment of the present invention may be carried out using various topical formulations containing triamcinolone acetonide, such as vaginal creams, vaginal gels, pessaries, vaginal effervescent tablets, vaginal ointments and the like. The preparation adopted by the treatment method of the invention has the functions of anti-inflammation and vasoconstriction, has the effects of reducing, lightening and disappearing the erosion area and has the effect of inhibiting the recurrence of cervical erosion.
Description
Technical field
The present invention relates to a kind of compound preparation of treating cervical erosion, belong to medical technical field.
Background technology
Cervical erosion is women's frequently-occurring disease and commonly encountered diseases.Especially married, as to have given birth to women, almost 60～80% cervical erosion that have in various degree.Cervical erosion can cause leucorrhoea grow in quantity, leucorrhea band blood or postcoital bleeding, and sore waist and aching in the waist and the back, menoxenia, sterility and infertility etc. are often arranged.Serious cervical erosion is as treating, and cervix uteri precancerous lesion or cervical cancer can take place minority.Cervical erosion be because childbirth, miscarriage, obstetric infection or operation technique or mechanical stimulus such as sexual life damage cervix uteri, pathogen is invaded and is caused to infect and cause.Artificial abortion can cause cervix uteri damage in various degree repeatedly, gives the pathogenic bacteria opportunity, causes cervicitis.Because the stimulation of inflammation, merocrine secretion's thing increases, and cervix uteri is immersed in the rheuminess thing for a long time will cause erosion.Cervical erosion is divided by the size of rotten to the corn area, can be divided into light, in, weigh three degree.When rotten to the corn area less than whole cervix uteri area 1/3 the time be slight cervical erosion; Rotten to the corn area account for the cervix uteri area 1/3～2/3 between the person rotten to the corn for moderate; It is rotten to the corn for severe that rotten to the corn area accounts for whole cervix uteri area 2/3 above person.At present Drug therapy is taked in the treatment of cervical erosion usually both at home and abroad, three kinds of methods of naturopathy and operative treatment:
1. the side effect of Drug therapy is little, and the women who is fit to not fertility uses.The medicine of common treatment cervical erosion have disappear rotten clever gel with control Mi Lingshuan.
2. moderate cervical erosion and moderate and severe cervical patient can not reach recovery from illness usually with existing Drug therapy.Will adopt naturopathy such as electric rubbing hot medicated compress, laser therapy, cryotherapy thus.The shortcoming of physiotherapy is that side effect is bigger, might cause the vaginal walls nerve sensitivity to reduce, and is influential to life quality.Cure the back easy relapse in addition.
3. as above-mentioned failing to respond to any medical treatment, or cervical hypertrophy is arranged, or rotten to the corn face is dark and wide, and the person that involves the cervical canal, can consider row conization of cervix or panhysterectomy.
Summary of the invention
The present invention is directed to the deficiency of prior art, a kind of method of treating cervical erosion is provided, it is characterized in that using the topical preparation of containing triamcinolone acetonide treatment cervical erosion is treated.Therapeutic Method of the present invention has antiinflammatory and vasoconstriction function, rotten to the corn area is dwindled, shoals and the useful effect that disappeared, and the recurrence that suppresses cervical erosion is had good curative effect.
The method of treatment cervical erosion of the present invention comprises medicine and pharmaceutic adjuvant, and drug component wherein is:
Triamcinolone acetonide 0.01～99.9 percentage by weight
Other drug and pharmaceutic adjuvant 0.1～99.99 percentage by weight
The method of treatment cervical erosion provided by the invention can adopt the various topical dosage forms that contain triamcinolone acetonide, and these different dosage forms need be added different pharmaceutic adjuvants.
Specify as follows:
The vaginal cream agent is except that containing drug components such as triamcinolone acetonide, and used pharmaceutic adjuvant is substrate 0.1～99.99 percentage by weight: comprise the biological mucosa adhesive agent, emulsifying agent, emollient, and cosolvent.
Above-mentioned biological mucosa adhesive agent is selected from the one or more combination in chitosan and the derivant thereof.
Above-mentioned emulsifying agent is selected from tristerin, stearyl alcohol, hexadecanol, the stearic alcohol ether of Polyethylene Glycol, the one or more combination in the Polyethylene Glycol hexadecanol ether.
Above-mentioned emollient is selected from the cetyl cetylate, octyl stearate, the different monooctyl ester of stearic acid, oleic acid decanol, isopropyl myristate, Vitamin E acetate, the one or more combination in the sad cocoa ester.
Above-mentioned cosolvent is selected from glycerol, polysorbate 60, polyoxyethylene sorbitan monoleate, the one or more combination in the propylene glycol.
The method for preparing of this vaginal cream agent may further comprise the steps:
1) gets emulsifying agent, the emollient heat fused;
2) place cosolvent to dissolve triamcinolone acetonide;
3) place water to dissolve the biological mucosa adhesive agent, and the adjusting PH is 4-5;
4) with other drug (if any) or adjuvant place 3) dissolving;
5) with 1), 2) and 4) under heating, stir.
Vagina gel is except that containing drug components such as triamcinolone acetonide, and used pharmaceutic adjuvant is substrate 0.1～99.99 percentage by weight:
Above-mentioned substrate is chitosan, gelatin, pectin, Acritamer 940, methylcellulose, sodium carboxymethyl cellulose, cross linked sodium polyacrylate, the one or more combination in the Polyethylene Glycol.
The method for preparing of this vagina gel may further comprise the steps:
Substrate is processed hydrogel matrix, add again triamcinolone acetonide and other drug (if any), mixing adds water to capacity, stirs promptly to get.
Vaginal suppository is except that containing drug components such as triamcinolone acetonide, and used pharmaceutic adjuvant is substrate 0.1～99.99 percentage by weight:
Above-mentioned substrate is chitosan, gelatin, pectin, Acritamer 940, Polyethylene Glycol, Myrj 52, the one or more combination in the cocoa butter.
The method for preparing of this vaginal suppository may further comprise the steps:
1) gets the substrate heat fused;
2) get triamcinolone acetonide and other drug (if any) under agitation add above-mentioned substrate, fully stir, irritate mould and promptly get.
The vagina effervescence agent is except that containing drug component such as triamcinolone acetonide, and used pharmaceutic adjuvant is effervescent tablet disintegrating agent acid 5～45 percentage by weights and effervescent tablet disintegrating agent alkali 5～45 percentage by weights mutually mutually:
Above-mentioned effervescent tablet disintegrating agent acid is citric acid mutually, tartaric acid, and one or more in the sodium dihydrogen phosphate, the acid of described effervescent tablet disintegrating agent is sodium bicarbonate or sodium carbonate mutually.
The method for preparing of this vagina effervescence agent may further comprise the steps:
1) get triamcinolone acetonide, other drug (if any) cross 100 mesh sieves mutually respectively with the acid of effervescent tablet disintegrating agent, mixing is crossed the wet grain of sieve series, in 40～60 ℃ of dryings;
2) get effervescent tablet disintegrating agent alkali and cross 100 mesh sieves mutually, cross the wet grain of sieve series, in 40～60 ℃ of dryings;
3) with 1) and 2) dry granular that makes mixes, and adds the moderate lubrication agent, mixing, tabletting promptly gets.
Vaginal tablet is except that containing drug components such as triamcinolone acetonide, and used pharmaceutic adjuvant is substrate 0.1～99.99 percentage by weight:
The disintegrating agent of above-mentioned vaginal tablet is a starch, microcrystalline Cellulose, the one or more combination in the carboxymethyl starch sodium.
The method for preparing of this vaginal tablet may further comprise the steps:
Get triamcinolone acetonide, other drug (if any) and disintegrating agent cross 100 mesh sieves respectively, mixing is crossed the wet grain of sieve series, in 40～60 ℃ of dryings; Add the moderate lubrication agent, mixing, tabletting promptly gets.
The vagina ointment is except that containing drug components such as triamcinolone acetonide, and used pharmaceutic adjuvant is substrate 0.1～99.99 percentage by weight:
The substrate of above-mentioned vagina ointment is selected from mineral oil, Polyethylene Glycol, and polyethylene etc., water-soluble binder is selected from gelatin, pectin, xanthan gum, sodium carboxymethyl cellulose, methylcellulose, oxidic polyethylene etc.
The method for preparing of this vagina ointment may further comprise the steps:
1) triamcinolone acetonide is placed mineral oil, Polyethylene Glycol calorifies 35 ℃ of fusing dissolvings in the methylcellulose;
2) with gelatin, pectin, xanthan gum, sodium carboxymethyl cellulose, oxidic polyethylene mix homogeneously;
3) with 1) and 2) under heating 40 ℃, stir.
The beneficial effect that the present invention brings is: the deficiency to prior art, a kind of method of treating cervical erosion is provided, and it is characterized in that using the topical preparation of containing triamcinolone acetonide treatment cervical erosion is treated.Therapeutic Method of the present invention has antiinflammatory and vasoconstriction function, rotten to the corn area is dwindled, shoals and the useful effect that disappeared, and the recurrence that suppresses cervical erosion is had good curative effect.
The specific embodiment
Embodiment 1
Prescription is formed:
Preparation process:
1) get tristerin, stearyl alcohol, cetyl cetylate, octyl stearate calorify 80 ℃ of fusings.
2) triamcinolone acetonide is placed glycerol, polysorbate 60 dissolves in the polyoxyethylene sorbitan monoleate.
3) place water to dissolve the agent of high viscosity chitosan, and use lactic acid adjusting PH to be 4-5.
4) metronidazole is placed 3) dissolving.
5) with 1), 2) and 4) be stirred into emulsifiable paste in heating under 40 ℃.
Embodiment 2
Prescription is formed:
Preparation process:
1) get tristerin, stearyl alcohol, cetyl cetylate, octyl stearate calorify 80 ℃ of fusings;
2) triamcinolone acetonide is placed glycerol, polysorbate 60 dissolves in the polyoxyethylene sorbitan monoleate;
3) place water to dissolve the agent of high viscosity chitosan, and use lactic acid adjusting PH to be 4-5;
4) clindamycin is placed 3) dissolving;
5) with 1), 2) and 4) emulsifiable paste stirs under heating 40 ℃.
Embodiment 3
Prescription is formed:
Preparation process:
1) the stearic alcohol ether of taking polyethylene glycol, hexadecanol, isopropyl myristate, Vitamin E acetate calorify 80 ℃ of fusings;
2) triamcinolone acetonide is placed glycerol, polysorbate 60 dissolves in the polyoxyethylene sorbitan monoleate;
3) place water to dissolve the agent of high viscosity chitosan, and use lactic acid adjusting PH to be 4-5;
4) metronidazole is placed 3) dissolving;
5) with 1), 2) and 4) emulsifiable paste stirs under heating 40 ℃.
Embodiment 4
Prescription is formed:
Preparation process:
1) triamcinolone acetonide is placed propylene glycol, polysorbate 60 dissolves in the polyoxyethylene sorbitan monoleate;
2) place water to dissolve the agent of high viscosity chitosan, and use lactic acid adjusting PH to be 4-5;
3) metronidazole is placed 2) dissolving;
5) with 1) and 3) emulsifiable paste stirs under heating 40 ℃.
Embodiment 5
Prescription is formed:
Preparation process:
1) triamcinolone acetonide is placed mineral oil, calorify 35 ℃ of fusing dissolvings in the polyethylene;
2) with gelatin, pectin and sodium carboxymethyl cellulose place water to dissolve;
3) with 1) and 2) ointment stirs under heating 40 ℃.
Embodiment 6
Prescription is formed:
Preparation process:
1) triamcinolone acetonide is placed mineral oil, Polyethylene Glycol calorifies 35 ℃ of fusing dissolvings in the methylcellulose;
2) with gelatin, pectin, xanthan gum, sodium carboxymethyl cellulose, oxidic polyethylene mix homogeneously;
3) with 1) and 2) ointment stirs under heating 40 ℃.
Clinical effectiveness
For the slight patients of cervical ruin of 8 examples, adopt the triamcinolone acetonide ointment to treat, once a day, treated five days, clinical symptom disappearance, the cervix uteri epithelium restores fully.Check after January, show no cervical erosion recurrence.The patient feels well, does not have uncomfortable.
For 12 routine moderate patients of cervical ruin, adopt the triamcinolone acetonide ointment to treat, once a day, treat a week, clinical symptom disappearance, the cervix uteri epithelium restores fully.Check after January, show no cervical erosion recurrence.The patient feels well, does not have uncomfortable.
For 12 routine moderate and severe cervical patients, adopt the treatment of triamcinolone acetonide ointment, once a day, treat a week, clinical symptoms is clearly better, and cervix uteri epithelial erosion face obviously reduces.The patient feels well, no significant discomfort.
Claims (12)
1. method with the preparation for treating cervical erosion that contains triamcinolone acetonide is characterized in that adopting the topical preparation of containing triamcinolone acetonide cervical erosion is treated or to prevent.
2. a kind of usefulness as claimed in claim 1 contains the method for the preparation for treating cervical erosion of triamcinolone acetonide, it is characterized in that, the described preparation that is used to treat cervical erosion contains the triamcinolone acetonide of 0.01～99.9 percentage by weight.
3. a kind of usefulness as claimed in claim 2 contains the method for the preparation for treating cervical erosion of triamcinolone acetonide, it is characterized in that, the described preparation that is used to treat cervical erosion contains the pharmaceutic adjuvant of 0.1～99.99 percentage by weight.
4. a kind of usefulness as claimed in claim 3 contains the method for the preparation for treating cervical erosion of triamcinolone acetonide, it is characterized in that the described preparation that is used to treat cervical erosion is the vaginal cream agent.Described pharmaceutic adjuvant is substrate 0.1～99.99 percentage by weight.Described substrate contains biological mucosa adhesive agent, emulsifying agent, emollient, cosolvent.Above-mentioned biological mucosa adhesive agent is selected from the one or more combination in chitosan and the derivant thereof.Above-mentioned emulsifying agent is selected from tristerin, stearyl alcohol, hexadecanol, the stearic alcohol ether of Polyethylene Glycol, the one or more combination in the Polyethylene Glycol hexadecanol ether.Above-mentioned emollient is selected from the cetyl cetylate, octyl stearate, the different monooctyl ester of stearic acid, oleic acid decanol, isopropyl myristate, Vitamin E acetate, the one or more combination in the sad cocoa ester.Above-mentioned cosolvent is selected from glycerol, polysorbate 60, polyoxyethylene sorbitan monoleate, the one or more combination in the propylene glycol.
5. a kind of usefulness as claimed in claim 3 contains the method for the preparation for treating cervical erosion of triamcinolone acetonide, it is characterized in that the described preparation that is used to treat cervical erosion is a vagina gel.Described pharmaceutic adjuvant is substrate 0.1～99.99 percentage by weight.Described substrate is selected from chitosan, gelatin, pectin, Acritamer 940, methylcellulose, sodium carboxymethyl cellulose, cross linked sodium polyacrylate, the one or more combination in the Polyethylene Glycol.
6. a kind of usefulness as claimed in claim 3 contains the method for the preparation for treating cervical erosion of triamcinolone acetonide, it is characterized in that the described preparation that is used to treat cervical erosion is a vaginal suppository.Described pharmaceutic adjuvant is substrate 0.1～99.99 percentage by weight.Described substrate is selected from chitosan, gelatin, pectin, Acritamer 940, Polyethylene Glycol, Myrj 52, the one or more combination in the cocoa butter.
7. a kind of usefulness as claimed in claim 3 contains the method for the preparation for treating cervical erosion of triamcinolone acetonide, it is characterized in that the described preparation that is used to treat cervical erosion is a vagina effervescence.Described pharmaceutic adjuvant is effervescent tablet disintegrating agent acid 0.1～45 percentage by weight and effervescent tablet disintegrating agent alkali 0.1～45 percentage by weight mutually mutually.The acid of described effervescent tablet disintegrating agent is selected from citric acid mutually, tartaric acid, and one or more in the sodium dihydrogen phosphate, the acid of described effervescent tablet disintegrating agent is selected from sodium bicarbonate or sodium carbonate mutually.
8. a kind of usefulness as claimed in claim 3 contains the method for the preparation for treating cervical erosion of triamcinolone acetonide, it is characterized in that the described preparation that is used to treat cervical erosion is a vaginal tablet.Described pharmaceutic adjuvant is disintegrating agent 0.1～99.99 percentage by weight.Described disintegrating agent is selected from starch, microcrystalline Cellulose, the one or more combination in the carboxymethyl starch sodium.
9. a kind of usefulness as claimed in claim 3 contains the method for the preparation for treating cervical erosion of triamcinolone acetonide, it is characterized in that the described preparation that is used to treat cervical erosion is the vagina ointment.Described pharmaceutic adjuvant is substrate 0.1～99.99 percentage by weight.The substrate of above-mentioned vagina ointment is selected from mineral oil, Polyethylene Glycol, and polyethylene etc., water-soluble binder is selected from gelatin, pectin, xanthan gum, sodium carboxymethyl cellulose, the one or more combination in the oxidic polyethylene.
10. a kind of usefulness as claimed in claim 1 contains the method for the preparation for treating cervical erosion of triamcinolone acetonide, it is characterized in that, the described preparation that is used to treat the cervical erosion method contains one or more antibiotic.
11. a kind of usefulness as claimed in claim 10 contains the method for the preparation for treating cervical erosion of triamcinolone acetonide, it is characterized in that, described antibiotic is selected from metronidazole, tinidazole, ornidazole, clindamycin, azithromycin, clotrimazole, nitre miconazole, Nitric acid butoconazole.
12. a kind of usefulness as claimed in claim 10 contains the method for the preparation for treating cervical erosion of triamcinolone acetonide, it is characterized in that, the described preparation that is used to treat the cervical erosion method contains one or more antibiotic of 0.01～50 percentage by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103187957A CN102416018A (en) | 2011-10-13 | 2011-10-13 | Method for treating cervical erosion by using preparation containing triamcinolone acetonide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103187957A CN102416018A (en) | 2011-10-13 | 2011-10-13 | Method for treating cervical erosion by using preparation containing triamcinolone acetonide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102416018A true CN102416018A (en) | 2012-04-18 |
Family
ID=45940821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103187957A Pending CN102416018A (en) | 2011-10-13 | 2011-10-13 | Method for treating cervical erosion by using preparation containing triamcinolone acetonide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102416018A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1856294A (en) * | 2003-08-25 | 2006-11-01 | 弗米克斯有限公司 | Osmotic drug foam |
-
2011
- 2011-10-13 CN CN2011103187957A patent/CN102416018A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1856294A (en) * | 2003-08-25 | 2006-11-01 | 弗米克斯有限公司 | Osmotic drug foam |
Non-Patent Citations (3)
| Title |
|---|
| 孟庆华: "微波配合曲安奈德治疗复发性宫颈息肉的疗效观察", 《临床误诊误治》, vol. 17, no. 12, 31 December 2004 (2004-12-31), pages 841 * |
| 潘小利: "硝酸咪康唑栓联合曲安奈德益康唑乳膏治疗外阴阴道假丝酵母菌病", 《当代医学》, vol. 17, no. 9, 31 March 2011 (2011-03-31), pages 6 - 7 * |
| 黄雪松等: "宫颈糜烂临床治疗进展", 《临床军医杂志》, vol. 34, no. 3, 30 June 2006 (2006-06-30), pages 351 - 353 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101175503B (en) | Composition and method for regulating and remaining vaginal flora and vaginal acidity be normal | |
| CN108635585A (en) | A kind of pharmaceutical composition for treating senile vahinitis and temperature sensitive slow-releasing gel used and preparation method | |
| KR20210119188A (en) | Feminine vulva cleanser and method for producing the same | |
| CN101069726B (en) | Chinese medicine preparation of expelling toxin by cooling and eliminating damp and removing stasis, preparing method and use | |
| CN104274741A (en) | Medicinal composition and medicinal sanitary napkin for treating gynecological diseases | |
| CN102038679B (en) | Metronidazole, clotrimazole and chlorhexidine acetate vaginal gel and preparation method thereof | |
| CN101797269A (en) | Physiological balance liquid for adjusting microecology in vaginas of women | |
| CN1943600B (en) | Medicinal composition containing American cockroach and its ethanol extract and new use | |
| CN104721418B (en) | It is a kind of to be used to treat pharmaceutical composition of gynaecological imflammation and preparation method thereof and purposes | |
| CN102416018A (en) | Method for treating cervical erosion by using preparation containing triamcinolone acetonide | |
| CN102846802B (en) | Capsule for treating urinary system diseases and preparation method thereof | |
| CN102641277B (en) | Ointment for treating gynaopathy and dermatoses and preparation method thereof | |
| CN101837067A (en) | Medicinal composition for curing gynecological diseases and preparation method thereof | |
| CN110327287A (en) | It is a kind of for prevent and treat vaginitis containing lactose prod and its production technology | |
| CN102552665A (en) | Externally-applied traditional Chinese medicine composition for treating gynecological diseases | |
| CN104983983A (en) | Traditional Chinese medicine composition for treating gynecological disease and preparation thereof | |
| CN101721395A (en) | Water soluble gel containing xylitol and application thereof in medicine for treating cervical erosion | |
| RU2150944C1 (en) | Method of treatment of patient with bacterial vaginitis | |
| CN101618192A (en) | Pharmaceutical application of pharmaceutical composition containing zedoary turmeril oil | |
| CN102225196A (en) | Application of superoxide dismutase in preparing drugs for treating diseases of cervical erosion and colpitis | |
| CN102366567B (en) | Pharmaceutical composition for treating condyloma acuminatum, and preparation and application method | |
| CN110448615A (en) | A kind of Chinese medicine composition for treating gynaecological imflammation, drug and preparation method thereof | |
| CN101647954A (en) | Traditional Chinese medicine for treating cervicitis and preparation method and application thereof | |
| RU2127595C1 (en) | Method of treatment of patients with inflammatory sickness of female gonads in reproductive age | |
| CN102048752B (en) | Medicament for treating vaginitis and cervical erosion , and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120418 |